Literature DB >> 18043240

Chronic idiopathic neutropenias and severe congenital neutropenia.

Jan Palmblad1, Helen A Papadaki.   

Abstract

PURPOSE OF REVIEW: Chronic idiopathic and severe congenital neutropenias are rare disorders for which recent discoveries have highlighted mechanisms and consequences. RECENT
FINDINGS: An inflammatory bone marrow milieu has been shown to be a major contributor to the pathophysiology of chronic idiopathic neutropenia. Activated T-lymphocytes with myelosuppressive properties and pro-apoptotic mediators, such as IFNgamma, TNFalpha, Fas-ligand and TGFbeta1 result in accelerated apoptosis of granulocytic progenitor cells. Decreased levels of the anti-inflammatory cytokine IL-10 further disturb the balance between survival and pro-apoptotic mediators in chronic idiopathic neutropenia. Mutations in the HAX1 gene are associated with most cases of recessive autosomal severe congenital neutropenia, while ELA2 mutations are found in most cases of autosomal dominant and sporadic cases. The role of HAX-1 protein as a regulatory step in apoptosis provides further evidence for severe congenital neutropenia as a disorder of programmed cell death. The preleukemic character of severe congenital neutropenia, particularly for patients with need for high granulocyte colony stimulating factor dosage, was recently emphasized.
SUMMARY: Chronic idiopathic (or as recent data suggest, immunologic) and severe congenital neutropenias provide intriguing models for better understanding of regulation of myelopoiesis. Similarities and differences between the two disorders might help to dissect these regulatory events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18043240     DOI: 10.1097/MOH.0b013e3282f172d3

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  6 in total

1.  Clonal patterns of X-chromosome inactivation in peripheral blood cells of female patients with chronic idiopathic neutropenia.

Authors:  Semeli Mastrodemou; Vasilios Vazgiourakis; Maria Velegraki; Konstantia Pavlaki; George N Goulielmos; Helen A Papadaki
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

2.  Abnormal telomere shortening of peripheral blood mononuclear cells and granulocytes in patients with chronic idiopathic neutropenia.

Authors:  Konstantia I Pavlaki; Maria-Christina Kastrinaki; Michail Klontzas; Maria Velegraki; Irene Mavroudi; Helen A Papadaki
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

3.  Increased levels of the high mobility group box 1 protein sustain the inflammatory bone marrow microenvironment in patients with chronic idiopathic neutropenia via activation of toll-like receptor 4.

Authors:  Maria Velegraki; Helen Koutala; Christos Tsatsanis; Helen A Papadaki
Journal:  J Clin Immunol       Date:  2011-11-30       Impact factor: 8.317

Review 4.  Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

5.  Incidence of Severe Chronic Neutropenia in South Korea and Related Clinical Manifestations: A National Health Insurance Database Study.

Authors:  Nuri Lee; Boung Chul Lee
Journal:  Medicina (Kaunas)       Date:  2020-05-27       Impact factor: 2.430

6.  Osteocytes regulate neutrophil development through IL-19: a potent cytokine for neutropenia treatment.

Authors:  Min Xiao; Wuju Zhang; Wen Liu; Linlin Mao; Jincheng Yang; Le Hu; Sheng Zhang; Yaling Zheng; Anling Liu; Qiancheng Song; Yuhua Li; Guozhi Xiao; Zhipeng Zou; Xiaochun Bai
Journal:  Blood       Date:  2021-06-24       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.